Does serial administration of gadolinium‐based contrast agents affect patient neurological and neuropsychological status? Fourteen‐year follow‐up of patients receiving more than fifty contrast administrations

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F20%3A00008616" target="_blank" >RIV/00023884:_____/20:00008616 - isvavai.cz</a>

Výsledek na webu

<a href="https://onlinelibrary.wiley.com/doi/full/10.1002/jmri.26948" target="_blank" >https://onlinelibrary.wiley.com/doi/full/10.1002/jmri.26948</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Does serial administration of gadolinium‐based contrast agents affect patient neurological and neuropsychological status? Fourteen‐year follow‐up of patients receiving more than fifty contrast administrations

Popis výsledku v původním jazyce

Gadolinium‐based contrast agents (GBCAs) have been in clinical use for ~30 years and have been considered relatively safe in terms of acute allergy‐like and chemotoxic reactions.1 The demonstration of increased signal intensity (SI) in the brain, particularly in the deep brain nuclei (dentate nucleus [DN] and globus pallidus [GP]) on unenhanced T1‐weighted images following cumulative GBCA dosing and evidence of the presence of gadolinium (Gd) in these nuclei (and elsewhere)2 has generated concern over potential long‐term detrimental effects of these agents, potentially leading to severe neurological deficits. As yet, however, no clinical manifestations of Gd toxicity or adverse clinical outcomes related to brain Gd retention have been observed following the repeated administration of any GBCA. Nevertheless, all linear GBCAs have been suspended in Europe with the exception of two substituted linear agents (MultiHance, Bracco Diagnostics, Princeton, NJ; and Primovist, Bayer Healthcare, Berlin, Germany) that are uniquely specific for liver imaging. The rationale for the suspension has been stated as: "to prevent any risks that could potentially be associated with gadolinium brain deposition."3 The basal ganglia and DN are primarily involved in cognitive processing and motor control.4 Damage to the DN and GP may therefore be expected to result predominantly in movement disorder manifestations such as resting tremor, rigidity, bradykinesia, and gait abnormalities, as well as cognitive impairment, depression, and neurobehavioral deficits. We therefore aimed to assess the neurological and neuropsychological status of four patients who received exceptionally large cumulative doses of GBCAs over many years at our center for the diagnosis and follow‐up of glioblastoma multiforme (GBM).

Název v anglickém jazyce

Does serial administration of gadolinium‐based contrast agents affect patient neurological and neuropsychological status? Fourteen‐year follow‐up of patients receiving more than fifty contrast administrations

Popis výsledku anglicky

Gadolinium‐based contrast agents (GBCAs) have been in clinical use for ~30 years and have been considered relatively safe in terms of acute allergy‐like and chemotoxic reactions.1 The demonstration of increased signal intensity (SI) in the brain, particularly in the deep brain nuclei (dentate nucleus [DN] and globus pallidus [GP]) on unenhanced T1‐weighted images following cumulative GBCA dosing and evidence of the presence of gadolinium (Gd) in these nuclei (and elsewhere)2 has generated concern over potential long‐term detrimental effects of these agents, potentially leading to severe neurological deficits. As yet, however, no clinical manifestations of Gd toxicity or adverse clinical outcomes related to brain Gd retention have been observed following the repeated administration of any GBCA. Nevertheless, all linear GBCAs have been suspended in Europe with the exception of two substituted linear agents (MultiHance, Bracco Diagnostics, Princeton, NJ; and Primovist, Bayer Healthcare, Berlin, Germany) that are uniquely specific for liver imaging. The rationale for the suspension has been stated as: "to prevent any risks that could potentially be associated with gadolinium brain deposition."3 The basal ganglia and DN are primarily involved in cognitive processing and motor control.4 Damage to the DN and GP may therefore be expected to result predominantly in movement disorder manifestations such as resting tremor, rigidity, bradykinesia, and gait abnormalities, as well as cognitive impairment, depression, and neurobehavioral deficits. We therefore aimed to assess the neurological and neuropsychological status of four patients who received exceptionally large cumulative doses of GBCAs over many years at our center for the diagnosis and follow‐up of glioblastoma multiforme (GBM).

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30224 - Radiology, nuclear medicine and medical imaging

Projekt

<a href="/cs/project/NV18-04-00457" target="_blank" >NV18-04-00457: Detekce dynamiky retence gadolinia v mozku po aplikaci MR kontrastních látek pomocí alterace T1 a T2 relaxačních časů. Prospektivní studie</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů